Blue Care Network has selected OneOme®, an independent precision medicine company co-founded by Mayo Clinic, to collaborate with and bring you Blue Cross Personalized Medicine℠. This program provides eligible patients a RightMed® PGx Test kit at no cost* to them. If one of your patients is selected to participate in the program, we hope you’ll help answer patient questions and encourage their participation.

PGx Lab Reports may be available prior to Clinical Action Plans (CAPs) within your Provider Portal. The CAP is a personalized summary of your patient’s test results with actionable next steps designed to help in the interpretation of the lab report. CAPs are usually posted 3-5 days after the PGx Lab Reports, so please check back or reach out if you don’t see them. Login here.

The RightMed Test by OneOme (cofounded by Mayo Clinic) uses the patient’s DNA to provide insight into how they may respond to certain medications based on their unique genetic makeup and guidelines established by the U.S. Food and Drug Administration, National Comprehensive Cancer Network and the Clinical Pharmacogenomics Implementation Consortium. Specific gene variants influence the rate of liver enzymes (e.g. Cytochrome p450) to metabolize medications. Ultrarapid metabolizers may convert prodrugs too quickly leading to a bolus of the active form; poor metabolizers may fail to clear the drug leading to toxicity. Relevant medications include opioids, mental health medications, antiplatelet agents, cardiovascular drugs, PPIs, oncology medications and more.